Hypofractionated radiotherapy in breast cancer: a 10-year single institution experience

Abstract

background: Moderately post-operative hypofractionated radiotherapy (hYpO-rT) for breast cancer is a safe and effective strategy as seen in large prospective trials. This study aimed to assess overall and disease-free survivals, local control, and acute and late toxicities in patients treated with hYpO-rT. Materials and methods: Data from patients submitted to post-operative hYpO-rT, with or without boost, were evaluated retrospectively. Demographic, disease, and treatment characteristics were collected. results: From March 2009 to December 2016, 393 patients were treated. Breast-conserving surgery was performed in 94.7%, immediate reconstruction after mastectomy in 6 (1.5%). Most patients (91.2%) had initial stage (0 to IIa), and chemotherapy was performed in 42.0%, hYpO-rT was mainly performed in 15 or 16 daily fractions of 267 cGy and 265 cGy, respectively. The median follow-up was 5.7 years. There were 25 deaths (6.4%) and 17 (4.3%) local recurrences. at 5 and 10 years, the overall survival, local control, and disease-free survival were, respectively, 96.0% and 79.3%, 99.2% and 94.9%, 96.6%, and 91.9%. acute grade 3 or 4 dermatitis was observed in 0.9%. Late grade 1 or 2 occurred in less than 3% of the patients. conclusion: hYpO-rT is a safe and effective radiotherapy regimen with excellent disease control and overall survival rates, with low acute and late toxicity rates.